Wall Street isn't convinced the Ozempic maker has a promising path back to sustainable growth as competition from Eli Lilly intensifies.
같은 분류의 다른 기사
- Why we're giving off-price retailer TJX a pass for softness in its biggest division위클리뉴스
- Target Q2 2026 earnings beat: sales up 5.3%, guidance raised위클리뉴스
- Scott Galloway Blasts SpaceX as “Crazy Overvalued.” Says the Stock Could Fall 90% From Here위클리뉴스
- Dow Jones Futures Fall After Sandisk, Micron, Credo Lead AI Losses; Target Earnings Beat위클리뉴스